Scientific Advisors

Max Krummel, PhD (Chair)

Professor, Department of Pathology, UCSF

Miriam Merad, MD, PhD

Professor of Oncological Science, Medicine and Immunology and a member of the Immunology Institute and The Tisch Cancer Institute, Mount Sinai School of Medicine

Stephen Hodi, MD

Director of the Melanoma Center and the Center for Immuno-Oncology, Dana-Farber Cancer Institute

Chloe Atreya, MD, PhD

Assistant Clinical Professor, Department of Medicine, UCSF


Max Krummel, PhD (Chair)

Professor, Department of Pathology, UCSF

Dr. Krummel is a Professor and the Robert E. Smith Endowed Chair in Experimental Pathology at UCSF. He studies mechanisms that regulate T cell response and immune function using cutting-edge real-time imaging methods. As a graduate student, he developed expertise in the generation and use of monoclonal antibodies targeted to costimulatory and inhibitory molecules on T cells. He generated antibodies to CTLA-4, which identified an inhibitory pathway of T cell regulation and also could be used to trigger or block that pathway. This approach led to the development of human antibodies of the same type, a therapy now named ‘ipilimumab’, which is FDA approved and widely used for treatment of melanoma and other cancers.

Dr. Krummel’s lab focuses on understanding how immune systems, collections of cells in complex tissues, work. The use of fluorescent proteins and real-time imaging enable the examination of information processing by the immune system. These approaches reveal how motile immune cells ‘search’ their environment for critical information and characterize specific phagocytes in the tumor microenvironments as primary players in transmitting signals to lymphocytes and regulating disease outcome.

Dr. Krummel earned his doctorate at UC Berkeley and did postdoctoral fellowships at Stanford University and the Walter and Eliza Hall Institute in Melbourne, Australia.

Miriam Merad, MD, PhD

Professor of Oncological Science, Medicine and Immunology and a member of the Immunology Institute and The Tisch Cancer Institute, Mount Sinai School of Medicine

Dr. Merad is the director of both the Precision Immunology Institute at Mount Sinai School of Medicine and the Mount Sinai Human Immune Monitoring Center (HIMC). She also co-directs the Cancer Immunology Program at the Mount Sinai Tisch Cancer Institute. Dr. Merad’s laboratory studies the contribution of macrophages and dendritic cells to cancer and inflammatory disease in mice and humans. Dr. Merad’s pioneering work mapping the regulatory network of dendritic cells (DCs) resulted in identification of a lineage of DC, the CD103+ DC, that is now considered a key target to improve antiviral and antitumor immunity. These insights, along with other significant discoveries, are now being used to develop novel macrophage and dendritic cell-specific targets for the treatment of cancer and inflammatory diseases.

Dr. Merad has authored more than 160 primary papers and reviews in high profile journals and receives funding from the National Institutes of Health (NIH) for her research on innate immunity and its contribution to human disease. Dr. Merad obtained her MD at the University of Algiers, Algeria. She did her residency in Hematology and Oncology in Paris, France and obtained her PhD in immunology in collaboration between Stanford University and University of Paris VII.

Stephen Hodi, MD

Director of the Melanoma Center and the Center for Immuno-Oncology, Dana-Farber Cancer Institute

Dr. Stephen Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber / Brigham and Women’s Cancer Center, the Sharon Crowley Martin Chair in Melanoma at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. Dr. Hodi is a graduate of Harvard University and Cornell University Medical College. He completed his postdoctoral training in Internal Medicine at the Hospital of the University of Pennsylvania and his medical oncology training at Dana-Farber cancer Institute, where he joined the faculty in 1998. His research focuses on gene therapy, the development of immune therapies, and first into human studies for malignant melanoma. Dr. Hodi is a member of the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the American Association for Cancer Research, the Eastern Cooperative Oncology Group Melanoma Committee, the Society for Immunotherapy of Cancer, the European Academy of Tumor Immunology and a founding member of the Society for Melanoma Research.

Dr. Hodi is an internationally recognized leader in the development of immune therapy and melanoma therapeutics. In particular, he is known for the clinical development of immune checkpoint inhibitors. His clinical investigation efforts have pioneered the use of immune checkpoint blockade and combinatorial approaches to treat cancer. His publications include articles in the Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and the New England Journal of Medicine.

Chloe Atreya, MD, PhD

Assistant Clinical Professor, Department of Medicine, UCSF

Dr. Atreya is a physician scientist in the Gastrointestinal Oncology Group at UCSF. She received an MD and PhD in Pharmacology from Yale University in 2005. After completing her internal medicine residency at the University of Washington, she joined UCSF as a Fellow in the Division of Hematology/Oncology. She continued as a Postdoctoral Scholar in the laboratory of Dr. Kevan Shokat. Dr. Atreya joined the UCSF faculty in 2013. In 2014, she attained certification in Advanced Training in Clinical Research and she has since served as the Principal Investigator on several clinical trials.

Her research focuses on the interplay of molecular markers and response to therapies for colorectal cancer, with the goal of improving patient outcomes and quality of life by personalizing treatment. Dr. Atreya is the recipient of numerous awards, including a NIH/NCI K08 Career Development Award for targeting of aberrant signaling in patient-derived colorectal cancer models and a 2018 R21 award to study the impact of the gut microbiome on metabolism or oral chemotherapy.